Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of ChAd155-RG Rabies Vaccine
NCT04019444Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2019
- Primary completion
- Mar 2023
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ChAd155-RG in rabies (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number and Percentage of Participants With Solicited Injection Site Reactogenicity Events, Number and Percentage of Participants With Solicited Systemic Reactogenicity Events and 4 more. Started Sep 2019; status: completed.
02
Drugs
ChAd155-RG
03
Conditions
rabies
Beyond the preview
Go deeper on NCT04019444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04019444.